gsk sales no big surprise to me, page-31

SilentP and Dinkum

Thanks for extracting that info, so with GSK's cost of sales at 26%, here is the financial summary for Relenza.

From latest Annual report, Relenza Sales $A192m

GSK takes 93% less 26% cost of sales = 67% = $A128.64m

Biota takes 7% = $$A9m

What a slap in the face!!!!

PC, are you listening???? Contract out the manufacturing of LANI and recruit some serious Sales People. Biota will immediately become a $10+ stock and you immediately can start funding some serious pipeline R&D or look at some serious acquisitions.

Alternatively, give DS the manufacturing, but only if you don't get screwed on costs.

PC - better still, Directors, are you listening??